Orthotopic GL261 glioma mouse model to test your immunomodulatory compound

07 Jul Orthotopic GL261 glioma mouse model to test your immunomodulatory compound

In vivo glioma mouse model recapitulating key human glioblastoma characteristics provide an invaluable resource to assess novel immunotherapy-based strategies aiming at bolstering immune system functions to ultimately improve treatment outcome.

Our validated syngeneic glioma mouse model, based on the intracerebral inoculation of Luc2-expressing GL261 cells which allow tumor growth monitoring by bioluminescence imaging, represents a suitable tool for chemo- and immunotherapy assessment. It shows reproducible and predictable growth characteristics and closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration, tumor-induced immunosuppression and astrogliosis. Interestingly, the use of immunocompetent syngeneic host makes it well-suited for studying glioma immunology and testing innovative drug candidates for their efficacy in enhancing the anti-tumor response alone or combined with reference therapies.

contact us

 I agree with the use of my personal data for further communications according to explicyte privacy policy

Orthotopic GL261 glioma mouse model to test your immunomodulatory compound